References

1. Rang, H.P. (2006) The receptor concept: Pharmacology's big idea. BrJPharmacol. 147, S9-S16.

2. Holmstedt, B. Liljestrand, G. (1981) Readings in Pharmacology. New York: Raven Press.

3. Clark,A.J.(1937) Generalpharmacology.InHeffter'sHandbuchDerExperimentellen Pharmakologie, Ergband 4. Berlin : Springer.

4. Clark, A.J. (1933) The Mode of Action ofDrugs on Cells. London: Edward Arnold.

5. Ariens, E.J. ( 1954 ) Affinity and intrinsic activity in the theory of competitive inhibition . Arch Int Pharmacodyn Ther. 99 , 32 - 49 .

6. Ariens, E.J. (1964) Molecular Pharmacology, Vol. 1. New York: Academic Press.

7. Van Rossum, J.M. (1966) Limitations of molecular pharmacology. Some implications of the basic assumptions underlying calculations on drug-receptor interactions and the significance of biological drug parameters. Adv Drug Res. 3,189-223.

8. Stephenson, R.P. (1956) A modification of receptor theory. Br J Pharmacol. 11, 379 - 393 .

9. Furchgott, R.F. (1966) The use of P-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res. 3, 21-55.

10. Furchgott, R.F. (1972) The classification of adrenoreceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In Handbook of Experimental Pharmacology, Catecholamines, Vol. 33, ed. H. Blaschko, E. Muscholl, pp. 283-335. Berlin : Springer- Verlag.

11. Kenakin, T.P. (1975) Blockade of histamine-induced contractions of intestinal smooth muscle by P-haloalkylamines. PhD thesis, University of Alberta, Edmonton, Alberta.

12. Black, J.W., Leff, P. (1983) Operational models of pharmacological agonist. Proc R Soc Lond [Biol]. 220,141-162.

13. Paton, W.D.M., Rang, H.P. (1965) The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc R Soc Lond [Biol]. 163,1-44.

14. Gaddum, J.H. (1937) The quantitative effects of antagonistic drugs. J Physiol Lond. 89, 7P-9P.

15. Ehlert, F.J. (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 33,187-194.

16. Kenakin, T.P. (2005) New concepts in drug discovery: Collateral efficacy and permissive antagonism. Nat Rev Drug Discov. 4 , 919 - 927 .

17. Kenakin, T.P., Jenkinson, S., Watson, C. (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists . J Pharmacol Exp Ther. 319 , 710 - 723 .

18. Price, M.R., Baillie, G.L., Thomas, A., Stevenson, L.A., Easson, M., Goodwin, R., McLean, A., Mcintosh, L., Goodwin, G., Walker, G., Westwood, P., Marrs, J., Thomson , F. , Cowley, P. , Christopoulos, A. , Pertwee, R.G. , Ross, R.A. ( 2005 ) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 68, 1484-1495.

19. Christopolous, A., Kenakin,T.P. (2002) G-protein coupled receptor allosterism and complexing. Pharmacol Rev. 54 , 323 - 374 .

20. Kew, J.N.C.,Trube, G., Kemp, J.A. (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effects of ifenprodil in rat cultured cortical neurons. J Physiol. 497 , 761 - 772 .

21. Cuatrecasas, P. (1974) Membrane receptors. Annu Rev Biochem. 43,169-214.

22. Katz, B.,Thesleff, S. (1957) A study of the "desensitization" produced by acetylcholine at the motor end-plate. J Physiol. 138, 63-80.

23. Del Castillo J., Katz B. (1957) Interaction at end-plate receptors between different choline derivatives. Proc R Soc London [Biol]. 146, 369-381.

24. Monod, J., Wyman, J., Changeux, J.P. (1965) On the nature of allosteric transitions. J Biol Chem. 12, 88-118.

25. Colquhoun, D. (1973) The relationship between classical and cooperative models for drug action. In Drug Receptors, ed. H.P. Rang, pp. 149-82. Baltimore, MD: University Park Press.

26. Karlin, A. (1967) On the application of a "plausible model" of allosteric proteins to the receptor for acetylcholine. J Theor Biol. 16, 306-320.

27. Thron, C.D. (1973) On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol Pharmacol. 9,1-9.

28. Burgen, A.S.V. (1966) Conformational changes and drug action. Fed Proc. 40, 2723 - 2728 .

29. DeLean, A., Stadel, J.M., Lefkowitz, R.J. (1980) A ternary complex model explains the agonist-specific binding properties of adenylate cyclase coupled P-adrenergic receptor. J Biol Chem. 255, 7108-7117.

30. Limbird, L.E., Lefkowitz, R.J. (1978) Agonist induced increase in apparent P-adrenergic receptor size. Proc Natl Acad Sci U S A. 75 , 228 - 232 .

31. Ross, E.M. , Maguire, M.E. , Sturgill , T.W. , Biltonen , R.L. , Gilman , A.G. ( 1977 ) Relationship between the P-adrenergic receptor and adenylate cyclase. J Biol Chem. 252 , 5761 - 5775 .

32. Samama, P., Cotecchia, S., Costa, T., Lefkowitz, R.J. (1993) A mutation-induced activated state of the P2-adrenergic receptor: Extending the ternary complex model. J Biol Chem. 268, 4625-4636.

33. Costa, T., Herz, A. (1989) Antagonists with negative intrinsic activity at S-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A. 86 , 7321 - 7325 .

34. Weiss, J.M., Morgan, P.H., Lutz, M.W., Kenakin,T.P. (1996) The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol. 178,151-167.

35. Weiss, J.M., Morgan, P.H., Lutz, M.W., Kenakin, T.P. (1996) The cubic ternary complex receptor- occupancy model. II. Understanding apparent affinity. J Theor Biol. 178 , 169 - 182 .

36. Weiss, J.M., Morgan, P.H., Lutz, M.W., Kenakin, T.P. (1996) The cubic ternary complex receptor- occupancy model. III. Resurrecting efficacy. J Theor Biol. 181 , 381 - 397 .

37. Roerig, S.C., Loh, H.H., Law, P.Y. (1992) Identification of three separate guanine nucleotide-biding proteins that interact with the S-opioid receptor in NG108-15 X glioma hybrid cells. Mol Pharmacol. 41, 822-831.

38. Laugwitz, K.L., Allgeier, A., Offermanns, S., Spicher, K., Van Sande, J., Dumont, J.E., Schultz, G. (1996) The human thyrotropin receptor: A heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci U S A. 93,116-120.

39. Gudermann, T., Kalbrenner, F., Schultz, G. (1996) Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol. 36, 429-459.

40. Hermans, E. (2003) Biochemical and pharmacological control of the multiplicity of coupling at G-protein receptors. Pharmacol Ther. 99 , 25 - 44 .

41. Albert, P.R., Robillard, L. (2002) G-protein specificity: Traffic direction required. Cell Signal. 14 , 407 - 418 .

42. Burford, N.T., Wang, D.X., Sadee, W. (2000) G-protein coupling of ^-opioid receptors (OP3) elevated basal signaling activity. Biochem J. 348, 531-537.

43. Offermanns, S., Wieland, T., Homann, D., Sandmann, J., Bombien, D., Spicher, K., Schultz, G., Jakobs, K.H. (1994) Transfected muscarinic acetylcholine receptors selectively couple to Gi-type proteins and Gq/11. Mol Pharmacol. 45, 890-898.

44. Wise, A., Sheehan, M., Rees, S., Lee, M., Milligan, G. (1999) Comparative analysis of the efficacy of A1 adenosine receptor activation of G/oa G proteins following coexpression of receptor and G protein and expression of A1 adenosine receptor G/-oa fusion proteins. Biochem. 38, 2272-2278.

45. Kohout, T.A., Lefkowitz, R.J. (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol. 63 , 9 - 18 .

46. Scott, M.G.H., Benmerah, A., Muntaner, O., Manullo, S. (2002) Recruitment of activated G protein-coupled receptors to pre-existing clathrin-coated pits in living cells. J Biol Chem. 277, 3552-3559.

47. DeWire, S.M., Ahn, S., Lefkowitz, R.J., Shenoy, S.K. (2007) ß-arrestins and cell signaling. Annu Rev Physiol. 69 , 483 - 510 .

48. Lefkowitz, R.J., Shenoy, S.K. (2005) Transduction of receptor signals by beta-arrestins. Science. 308, 212-217.

49. Terrillon, S., Bouvier, M. (2004) Receptor activity-independent recruitment of ß-arrestin reveals specific signaling modes. EMBO J. 23 , 3950 - 3961 .

50. Luttrell, L.M. (2005) Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J Mol Neurosci. 26 , 253 - 263 .

51. Azzi, M., Charest, P.G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M. (2003) ß-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc Natl Acad Sci USA. 100, 11406 - 11411 .

52. Seta, K., Nanmori, M., Modrall, J.G., Neubig, R.R., Sadoshima, J. (2002) AT1 receptor mutant lacking heterotrimeric G - protein coupling activates the Src - Ras - ERK pathway. J Biol Chem. 277, 9268-9277.

53. Wei, H., Ahn, S., Shenoy, S.K., Karnick, S.S., Hunyady, L., Luttrell, L.M., Lefkowitz, R.J. (2003) Independent ß-arrestin 2 and G-protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A. 100,10782-10787.

54. Gesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C.D., Wang S. (2006) Distinct ß-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 281,10856-10864.

55. Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P.H., Journot, L. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature. 365,170-175.

56. Fraunfelder, H., Parak, F., Young, R.D. (1988) Conformational substrates in proteins. Annu Rev Biophys Biophys Chem. 17,451-479.

57. Fraunfelder, H., Sligar, S.G., Wolynes, P.G. (1991) The energy landscapes and motions of proteins. Science. 254 , 1598 - 1603 .

58. Hilser, J., Freire, E. (1997) Predicting the equilibrium protein folding pathway: Structure-based analysis of staphylococcal nuclease. Proteins. 27,171-183.

59. Hilser, J., Dowdy, D., Oas, T.G., Freire, E. (1998) The structural distribution of cooperative interactions in proteins: Analysis of the native state ensemble. Proc Natl Acad Sci U S A. 95, 9903-9908.

60. Onaran , H.O. , Costa , T. ( 1997 ) Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci. 812, 98-115.

61. Onaran, H.O., Scheer, A., Cotecchia, S., Costa, T.A. (2000) A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor . In The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology, Vol. 148, ed. T.P. Kenakin, J.A. Angus, pp. 217-280. Heidelberg: Springer.

62. Kenakin, T.P. (1995) Agonist-receptor efficacy II: Agonist-trafficking of receptor signals. Trends Pharmacol Sci. 16, 232-238.

63. Kenakin,T.P. (1998) Agonist selective receptor states: The new level of selectivity? Pharm News. 5, 20-25.

64. Kenakin,T.P. (2002) Efficacy at G protein coupled receptors. Annual Rev Pharmacol Toxicol. 42 , 349 - 379 .

65. Kenakin,T.P. (2003) Ligand-selective receptor conformations revisited:The promise and the problem. Trends Pharmacol Sci. 24, 346-354.

66. Kenakin,T.P. (2006) Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin Drug Disc. 1, 635-652.

67. Urban, J.D., Clarke, W.P., von Zastrow, M., Nichols, D.E., Kobilka, B., Weinstein, H., Javitch, J.A., Roth, B.L., Christopoulos, A., Sexton, P.M., Miller, K.J., Spedding, M., Mailman, R.B. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 320,1-13.

68. Gether, U. , Lin , S. , Kobilka , B.K. ( 1995 ) Fluorescent labeling of purified ß2-adrenergic receptor: Evidence for ligand specific conformational changes. J Biol Chem. 270 , 28268 - 28275 .

69. Ghanouni, P., Gryczynski, Z., Steenhuis, J.J., Lee,T.W., Farrens, D. L. Lakowicz, J.R., Kobilka, B.K. (2001) Functionally different agonists produce distinct conformations in G-protein coupling domains of the ß2-adrenergic receptor. J Biol Chem. 276, 24433-24436.

70. Palanche, T. , Ilien , B. , Zoffmann , S. , Reck , M.P. , Bucher, B. , Edelstein , S.J. , Galzi , J.L. (2001) The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem. 276, 34853-34861.

71. Swaminath, G., Xiang, Y., Lee, T.W., Steehuis, J., Parnot, C., Kobilka, B.K. (2004) Sequential binding of agonists to the p2 adrenoceptor: Kinetic evidence for intermediate conformational states. J Biol Chem. 279, 686-691.

72. Hruby, V.J., Tollin, G. (2007) Plasmon-waveguide resonance (PWR) spectroscopy for directly viewing rates of GPCR/G-protein interactions and quantifying affinities. Curr Opin Pharmacol. 7, 507-514.

73. Rees, S., Morrow, D., Kenakin,T. (2002) PCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels. 8, 261-268.

74. Watson, C., Jenkinson, S., Kazmierski, W., Kenakin,T.P. (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol. 67,1268-1282.

75. Maeda, K., Nakata, H., Koh, Y., Miyakawa, T., Ogata, H., Takaoka, Y., Sbibayama, S., Sagawa, K., Fukushima, D., Moravek, J., Koyanagi, Y., Mitsuya, H. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/ CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol. 78, 8654-8662.

76. Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankuratri, S., Dioszegi, M. (2008) Molecular interactions of CCR5 with major classes of small-molecule anti - HIV CCR5 antagonists. Mol Pharmacol. 73 , 789 - 800 .

77. Kenakin,T. (2006) Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin Drug Discov. 1 , 635 - 652 .

78. Gray, J.A., Roth, B.L. (2001) Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Res Bull. 56 , 441 - 451 .

79. Hall, R.A., Premont, R.T., Leflowitz, R.J. (1999) Heptahelical receptor signaling: Beyond the G protein paradigm. J Cell Biol. 145, 927-932.

80. Heuss, C., Gerber, U. (2000) G-protein-independent signaling by G-protein-coupled receptors. Trends Neurosci. 23 , 469 - 475 .

81. Brady, A.E., Limbird, L.E. (2002) G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction . Cell Signal. 14, 297-309.

82. Lanier, S.M. (2004) AGS proteins, GPR motifs and the signals processed by het-erotrimeric G proteins. Biol Cell. 96 , 369 - 372 .

83. Hill, S.J. (2006) G-protein-coupled receptors: Past, present and future. Br J Pharmacol. 147 , S27 - S37 .

84. Kenakin, T.P., Onaran, O. (2002) The ligand paradox between affinity and efficacy: Can you be there and not make a difference? Trends Pharmacol Sci. 23, 275-280.

0 0

Post a comment